GEAP201914608A - Fused bicyclic heteroaryl derivatives having activity as phd inhibitors - Google Patents

Fused bicyclic heteroaryl derivatives having activity as phd inhibitors

Info

Publication number
GEAP201914608A
GEAP201914608A GEAP201914608A GEAP2019014608A GEAP201914608A GE AP201914608 A GEAP201914608 A GE AP201914608A GE AP201914608 A GEAP201914608 A GE AP201914608A GE AP2019014608 A GEAP2019014608 A GE AP2019014608A GE AP201914608 A GEAP201914608 A GE AP201914608A
Authority
GE
Georgia
Prior art keywords
activity
bicyclic heteroaryl
fused bicyclic
heteroaryl derivatives
phd inhibitors
Prior art date
Application number
GEAP201914608A
Other languages
English (en)
Georgian (ka)
Inventor
Natasha Kinsella
Susanne Wright
Hannah Canning
Devid Harrison
Kerry Jenkins
David Livermore
Saleh Ahmed
Gregory Barker
Richard Davenport
Original Assignee
Takeda Pharmaceuticals Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Takeda Pharmaceuticals Co filed Critical Takeda Pharmaceuticals Co
Publication of GEAP201914608A publication Critical patent/GEAP201914608A/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/12Drugs for disorders of the urinary system of the kidneys
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/04Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04Ortho-condensed systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D487/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04Ortho-condensed systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D519/00Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Epidemiology (AREA)
  • Plural Heterocyclic Compounds (AREA)
GEAP201914608A 2015-03-18 2016-03-17 Fused bicyclic heteroaryl derivatives having activity as phd inhibitors GEAP201914608A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB1504565.1A GB201504565D0 (en) 2015-03-18 2015-03-18 Novel compounds

Publications (1)

Publication Number Publication Date
GEAP201914608A true GEAP201914608A (en) 2019-10-10

Family

ID=53051992

Family Applications (2)

Application Number Title Priority Date Filing Date
GEAP201914608A GEAP201914608A (en) 2015-03-18 2016-03-17 Fused bicyclic heteroaryl derivatives having activity as phd inhibitors
GEAP201614608A GEP20207095B (en) 2015-03-18 2016-03-17 Fused bicyclic heteroaryl derivatives having activity as phd inhibitors

Family Applications After (1)

Application Number Title Priority Date Filing Date
GEAP201614608A GEP20207095B (en) 2015-03-18 2016-03-17 Fused bicyclic heteroaryl derivatives having activity as phd inhibitors

Country Status (31)

Country Link
US (1) US10287286B2 (https=)
EP (1) EP3271357B1 (https=)
JP (1) JP6726681B2 (https=)
KR (1) KR102609431B1 (https=)
CN (1) CN107531698B (https=)
AU (1) AU2016234209B2 (https=)
BR (1) BR112017019653B1 (https=)
CA (1) CA2979024C (https=)
CL (1) CL2017002354A1 (https=)
CO (1) CO2017009353A2 (https=)
CR (1) CR20170468A (https=)
DK (1) DK3271357T3 (https=)
DO (1) DOP2017000209A (https=)
EA (1) EA035739B1 (https=)
EC (1) ECSP17069696A (https=)
ES (1) ES2774052T3 (https=)
GB (1) GB201504565D0 (https=)
GE (2) GEAP201914608A (https=)
HU (1) HUE047918T2 (https=)
IL (1) IL254277B (https=)
MX (1) MX2017011902A (https=)
MY (1) MY194873A (https=)
NZ (1) NZ735631A (https=)
PE (1) PE20180656A1 (https=)
PH (1) PH12017501699B1 (https=)
PT (1) PT3271357T (https=)
SG (1) SG11201707280VA (https=)
TN (1) TN2017000384A1 (https=)
UA (1) UA123668C2 (https=)
WO (1) WO2016148306A1 (https=)
ZA (1) ZA201706612B (https=)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CR20180372A (es) 2016-02-24 2018-09-19 Pfizer Derivados de pirazolo [1,5-a] pirazin-4-ilo
WO2019034973A1 (en) 2017-08-14 2019-02-21 Pfizer Inc. PYRAZOLO [1,5-A] PYRAZIN-4-YL AND RELATED DERIVATIVES
JP7458987B2 (ja) * 2018-09-13 2024-04-01 キッセイ薬品工業株式会社 イミダゾピリジノン化合物
CN110950806A (zh) * 2019-11-14 2020-04-03 安庆博曼生物技术有限公司 四乙基氯化铵催化嘧啶环羟基氯代制备方法
JP7504822B2 (ja) * 2020-03-12 2024-06-24 キッセイ薬品工業株式会社 イミダゾピリジノン化合物を含む医薬組成物
US11718622B2 (en) 2020-03-16 2023-08-08 Exelixis Inc. Heterocyclic adenosine receptor antagonists
JP7612229B2 (ja) * 2020-04-20 2025-01-14 深▲チェン▼市塔吉瑞生物医薬有限公司 ピラジン置換ニコチンアミドの固体形態ならびにその調製および使用
JP7654071B2 (ja) * 2020-10-20 2025-03-31 アムジエン・インコーポレーテツド 複素環スピロ化合物及び使用方法
US12492178B2 (en) 2021-09-01 2025-12-09 Empathbio, Inc. Stable polymorph of R-MDMA HCl
WO2023072257A1 (en) 2021-10-28 2023-05-04 Insilico Medicine Ip Limited Prolyl hydroxylase domain-containing protein (phd) inhibitors and uses thereof
EP4447963A1 (en) * 2021-12-17 2024-10-23 Akebia Therapeutics Inc. Selective phd1 inhibitor compounds, compositions, and methods of use
US11912680B2 (en) 2021-12-28 2024-02-27 Empathbio, Inc. Nitric oxide releasing prodrugs of MDA and MDMA

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4209621A (en) 1979-04-27 1980-06-24 American Cyanamid Company (Substituted-phenyl)-1,2,4-triazolo[4,3-a]-pyrimidines and (substituted-phenyl)-1,2,4-triazolo[1,5-a]pyrimidines
DK135184A (da) * 1983-03-03 1984-10-10 Riker Laboratories Inc Triazol(4,3-c)- og triazol(1,5-c)pyrimidiner
US4572910A (en) * 1983-03-03 1986-02-25 Riker Laboratories, Inc. Triazolo[1,5-c]pyrimidines substituted by nitrogen-containing heterocyclic rings
AU2001273062B2 (en) 2000-06-30 2005-11-24 Wyeth Substituted-triazolopyrimidines as anticancer agents
JP2010065026A (ja) 2008-08-13 2010-03-25 Ishihara Sangyo Kaisha Ltd ピリジル−トリアゾロピリミジン誘導体又はその塩、並びにそれらを含有する有害生物防除剤
JP2010065024A (ja) 2008-08-14 2010-03-25 Ishihara Sangyo Kaisha Ltd トリアゾロピリミジン誘導体又はその塩を含有する有害生物防除剤
SI2455381T1 (sl) * 2009-07-17 2014-08-29 Japan Tobacco Inc. Triazolopiridinova spojina in njeno delovanje kot zaviralec prolil-hidroksilaze in induktor produkcije eritropoietina
JP2011168582A (ja) * 2010-01-21 2011-09-01 Ishihara Sangyo Kaisha Ltd トリアゾロピリジン誘導体又はその塩、それらの製造方法及びそれらを含有する有害生物防除剤
CA2881806A1 (en) 2012-08-23 2014-02-27 Mitsubishi Tanabe Pharma Corporation Pyrazolopyrimidine compound

Also Published As

Publication number Publication date
JP2018512408A (ja) 2018-05-17
JP6726681B2 (ja) 2020-07-22
BR112017019653B1 (pt) 2023-10-03
PE20180656A1 (es) 2018-04-17
IL254277B (en) 2020-10-29
WO2016148306A1 (en) 2016-09-22
ZA201706612B (en) 2019-01-30
AU2016234209B2 (en) 2020-08-27
HUE047918T2 (hu) 2020-05-28
CO2017009353A2 (es) 2017-11-30
CN107531698B (zh) 2024-08-13
MY194873A (en) 2022-12-21
CA2979024C (en) 2024-02-20
CR20170468A (es) 2018-04-27
CL2017002354A1 (es) 2018-05-04
HK1249512A1 (en) 2018-11-02
US20180072714A1 (en) 2018-03-15
ES2774052T3 (es) 2020-07-16
US10287286B2 (en) 2019-05-14
KR20170129874A (ko) 2017-11-27
EA201792057A1 (ru) 2018-04-30
EP3271357B1 (en) 2019-11-27
SG11201707280VA (en) 2017-10-30
CN107531698A (zh) 2018-01-02
PH12017501699A1 (en) 2018-03-12
NZ735631A (en) 2023-07-28
PT3271357T (pt) 2020-02-21
DK3271357T3 (da) 2020-02-17
EP3271357A1 (en) 2018-01-24
KR102609431B1 (ko) 2023-12-04
GEP20207095B (en) 2020-04-10
AU2016234209A1 (en) 2017-10-12
MX2017011902A (es) 2017-12-15
CA2979024A1 (en) 2016-09-22
EA035739B1 (ru) 2020-08-03
ECSP17069696A (es) 2018-02-28
BR112017019653A2 (pt) 2018-05-15
UA123668C2 (uk) 2021-05-12
DOP2017000209A (es) 2017-10-15
PH12017501699B1 (en) 2023-06-30
TN2017000384A1 (en) 2019-01-16
IL254277A0 (en) 2017-10-31
GB201504565D0 (en) 2015-05-06

Similar Documents

Publication Publication Date Title
GEAP201914608A (en) Fused bicyclic heteroaryl derivatives having activity as phd inhibitors
GEAP202215535A (en) Compounds
PH12020500529A1 (en) Bicyclic heterocyclyl derivatives as irak4 inhibitors
MX2022006783A (es) Nuevos derivados de metilquinazolinona.
EA202191286A1 (ru) Ингибитор 15-pgdh
WO2017205536A3 (en) Heterocyclic inhibitors of cbp/ep300 and their use in the treatment of cancer
EA201890200A1 (ru) Производные циклизированного сульфамоилариламида и их применение в качестве лекарственных препаратов для лечения гепатита b
EA201890594A1 (ru) Арильные, гетероарильные и гетероциклические соединения для лечения заболеваний
TR201904658T4 (tr) Bisiklik füzyonla birleştirilmiş heteroaril veya aril bileşikleri ve bunların ırak4 inhibitörleri olarak kullanımları.
MX390747B (es) Compuesto heterociclico sustituido con alquinilo, su metodo de preparacion y su uso medico.
PH12016501355A1 (en) Bicyclic heterocyclic derivatives as bromodomain inhibitors
MX394082B (es) Compuestos de tiazolcarboxamidas y piridinacarboxamida útiles como inhibidores de cinasa pim.
GEAP202115281A (en) Spirocycle compounds and methods of making and using same
GEP20186938B (en) Indolizine derivatives as phoshoinositide 3-kinases inhibitors
MY194116A (en) Pharmaceutical compounds
MX2018001992A (es) Compuestos triciclicos heterociclicos como inhibidores de fosfoinositol 3-quinasa.
MY181641A (en) Amino pyran ring derivative and composition and use thereof
SA519402103B1 (ar) 1,6-naphthyridine مشتقات 1، 6 نفثيرايدين CDK4/6 على شكل مثبط
GEAP202215588A (en) N-substituted-dioxocyclobutenylamino-3-hydroxypicolinamides useful as ccr6 inhibitors
EA201692298A1 (ru) Производные карбоксамидов
EA201700356A1 (ru) Новые циклопропанбензофуранилпиридопиразиндионы
MX379373B (es) Derivado de sulfonamida heterocíclico y medicina que contiene el mismo.
PH12019502170A1 (en) Combination of isoindolinone derivatives with sgi-110
AU2018264313A1 (en) Indolizine derivatives and application thereof in medicine
EA201892382A1 (ru) Замещенные бициклические гетероциклические соединения